Research programme: anticancer antibodies - Viventia/Affitech
Latest Information Update: 03 Feb 2011
At a glance
- Originator Affitech AS; Viventia Biotech
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Feb 2008 Preclinical development is ongoing
- 17 Aug 2005 BIO-2005 review
- 03 Feb 2005 Affitech has achieved a research milestone in the discovery and selection of several antibodies